Ligand Pharmaceuticals Inc (OQ:LGND)

Sector:  Healthcare Industry:  Pharmaceuticals
See Regulatory Filings on SEC
Company Contact
Address: 555 Heritage Drive, Suite 200
Tel: N/A
IR: See website
Key People
Matthew Edward Korenberg
President, Chief Operating Officer
Todd C. Davis
Chief Executive Officer, Director
Octavio Espinoza
Chief Financial Officer
Andrew Reardon
Chief Legal Officer
Business Overview
Ligand Pharmaceuticals Incorporated is a biopharmaceutical company enabling scientific advancement through supporting the clinical development of medicines. The Company does this by providing financing, licensing its technologies or both. Its Captisol platform technology is a chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. This technology has enabled several United States Food and Drug Administration (FDA)-approved products, including Gilead's Veklury, Amgen's Kyprolis, Baxter International's Nexterone, Melinta Therapeutics' Baxdela and Sage Therapeutics' Zulresso. Its technologies also include HepDirect, LTP and BEPro Technology Platform, SUREtechnology Platform (owned by Selexis), and Pelican Expression Technology. It has established multiple alliances, licenses and other business relationships with various pharmaceutical companies including Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences and Baxter International.
Financial Overview
For the three months ended 31 March 2024, Ligand Pharmaceuticals Inc revenues decreased 30% to $31M. Net income before extraordinary items increased 98% to $86.1M. Revenues reflect Milestone segment decrease of 95% to $727K, Teriparatide injection segment decrease of 42% to $2M. Net income reflects Gain from short-term investments increase from $39.5M to $110.8M (income), Other General and administrative decrease of 35% to $4.3M (expense).
Employees: 58 as of Dec 31, 2023
Reporting Currency: U.S. Dollars
Enterprise value: $1,505M as of Mar 31, 2024
Annual revenue (TTM): $118.31M as of Mar 31, 2024
EBITDA (TTM): $34.39M as of Mar 31, 2024
Net annual income (TTM): $96.34M as of Mar 31, 2024
Free cash flow (TTM): -$27.58M as of Mar 31, 2024
Net Debt Last Fiscal Year: N/A
Shares outstanding: 17,963,653 as of May 6, 2024
Index Membership: S&P 600 Small Cap
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

Thank you for visiting We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.